Tissium raises €30M in equity funding, €30M in debt
Summary
Tissium secured €30 million in equity funding and up to €30 million in debt financing. The company develops biomorphic programmable polymers that help repair damaged tissue without invasive stitches. It already has FDA-approved products for nerve repair and hernia treatment, and it plans to use the new capital to expand in the US and fund additional clinical trials. The company says it is moving into a commercial-stage MedTech phase while continuing to build its product pipeline.
Funding
Amount
$32.4M
Total raised
Date
June 24, 2026
Announcement date
Investors
Cathay Capital Private Equity
Lead investors
Company
tissium.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected